La Jolla Pharma (LJPC) 8.83 $LJPC
La Jolla Pharmaceutical Company Announces First-Quarter 2014 Financial Results
Business Wire - Wed Apr 30, 3:31PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
a leader in the development of therapeutics targeting significant unmet life-threatening diseases announces first-quarter 2014 financial results and highlights recent corporate progress.
La Jolla Pharmaceutical Company Announces Fourth-Quarter and Full-Year 2013 Financial Results and Highlights Recent Corporate Progress
Business Wire - Mon Mar 31, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, announces fourth-quarter and full-year 2014 financial results and highlights recent corporate progress.
La Jolla Pharmaceutical Company Receives Patent Allowance Covering Broad Range of Modified Pectin
Business Wire - Mon Mar 31, 7:01AM CDT
--Patent Covers Chronic Inflammatory Diseases including Chronic Kidney Disease and NASH
Technical Notes on Top Gainers -- Research on Sequenom, ImmunoCellular Therapeutics, Intellicheck Mobilisa, and La Jolla Pharma
PR Newswire - Thu Mar 20, 7:33AM CDT
On Wednesday, March 19, 2014, the US markets saw a negative sentiment with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including Sequenom Inc. (NASDAQ: SQNM), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), Intellicheck Mobilisa Inc. (AMEX: IDN), and La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Free technical research on SQNM, IMUC, IDN, and LJPC can be downloaded upon signing up at:
5 Stocks Poised for Breakouts
at The Street - Fri Mar 14, 12:25PM CDT
These stocks look ready to break out and trade higher from current levels.
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
Why La Jolla (LJPC) Is Surging Today
at The Street - Tue Mar 11, 2:38PM CDT
La Jolla Pharmaceutical (LJPC) stock is seeing an astronomical rise today on the heels of the news that the clinical trial for its gelectin inhibitor -- used to treat chronic kidney disease -- was a success.
La Jolla's Kidney Drug Is Statistical Noise but Stock Soars
at The Street - Tue Mar 11, 9:02AM CDT
Investors in a biotech stock bubble whistle past legitimate concerns about La Jolla's GCS-100.
La Jolla Pharmaceutical Company Reports Positive, Top-Line Results from Phase 2 Clinical Trial of GCS-100 in Chronic Kidney Disease
Business Wire - Mon Mar 10, 3:15PM CDT
--GCS-100 Well-tolerated
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
La Jolla Pharmaceutical Company to Present at 26th Annual ROTH Growth Stock Conference
Business Wire - Wed Mar 05, 7:01AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that George Tidmarsh, MD, PhD, President and CEO of La Jolla will be presenting a corporate update at the 26th Annual ROTH Conference on March 10, 2014 at 2:30 PM pacific time. An update on the phase 2 clinical study of GCS-100 for the treatment of chronic kidney disease will be included in the presentation. The presentation will be webcast and can be found on the Company's website www.ljpc.com after the presentation.
La Jolla Pharmaceutical Company and the George Washington University Enter Into Agreement for Technology Related to LJPC-501
Business Wire - Thu Feb 27, 7:02AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that it has signed an option agreement with the George Washington University ("GW" that will add proprietary technology to the Company's LJPC-501 program.
La Jolla Pharmaceutical Company Announces Final Dosing in Phase 2 Clinical Trial of GCS-100 in Chronic Kidney Disease
Business Wire - Fri Feb 21, 7:00AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease ("CKD" and has collected the final data for evaluation of the primary endpoint. The primary efficacy endpoint is the change in estimated glomerular filtration rate ("eGFR" from baseline to the average at Day 50 and 57 in each GCS-100 dose group compared to placebo. The primary endpoint will be reached if the difference in eGFR between either GCS-100 dose group and placebo has a significance of less than 10% (p-value of <0.1).
La Jolla Pharmaceutical Company Receives Notice of Allowance for Patent Claims Covering Modified Pectin for Treatment of Chronic Inflammation
Business Wire - Thu Feb 20, 7:00AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that the United States Patent and Trademark Office ("USPTO" has issued a notice of allowance for patent application number 13/888,158 covering methods of treating chronic inflammation using modified pectin. Specifically, the patent, which expires in 2025 without taking into account patent term extension, provides proprietary protection for methods of treating chronic inflammation by administration of modified pectin with a molecular weight greater than 25 kilodaltons.
La Jolla Pharmaceutical Company Forms Scientific Advisory Board
Marketwire - Wed Feb 12, 7:02AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a biotechnology company developing therapeutics targeting significant unmet life-threatening diseases, today announced the formation of a Scientific Advisory Board ("SAB" for the development of hepcidin ("LJPC-401" . Inaugural members of the SAB include Tomas Ganz, MD, PhD and Dr. Elizabeta Nemeth, PhD, both of the University of California, Los Angeles ("UCLA" . Dr. Ganz discovered the iron regulator peptide hepcidin and has revolutionized the field of iron biology. Dr. Nemeth has made significant contributions to the field of iron regulation and together with Dr. Ganz, created the first human hepcidin assay.
La Jolla Pharmaceutical Company and INSERM, Inserm Transfert Announce License Agreement to Develop Hepcidin Agonists
Marketwire - Mon Feb 10, 3:30PM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" and The French National Institute of Health and Medical Research ("INSERM" , today announced an exclusive worldwide license agreement to develop hepcidin agonists. Hepcidin is the body's master regulator of iron, and patients with insufficient hepcidin levels suffer from chronic iron overload, which can lead to organ and tissue damage. The Company plans to develop hepcidin agonists for the treatment of chronic iron overload in patients who are refractory to or intolerant to chelators.
Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
at The Street - Fri Feb 07, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
La Jolla Pharmaceutical Company to Present at the 16th Annual BIO CEO & Investor Conference
Marketwire - Wed Feb 05, 7:15AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria in New York City on February 10-11, 2014. George F. Tidmarsh, MD, PhD, President and Chief Executive Officer of La Jolla will present on La Jolla's recent progress at 4:30pm Eastern Time on Monday, February 10, in the Conrad Room. The presentation will also be available via webcast on the Company's website at http://www.ljpc.com.
La Jolla Pharmaceutical Company Announces First-Quarter 2014 Financial Results
Business Wire - Wed Apr 30, 3:31PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
a leader in the development of therapeutics targeting significant unmet life-threatening diseases announces first-quarter 2014 financial results and highlights recent corporate progress. La Jolla Pharmaceutical Company Announces Fourth-Quarter and Full-Year 2013 Financial Results and Highlights Recent Corporate Progress
Business Wire - Mon Mar 31, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, announces fourth-quarter and full-year 2014 financial results and highlights recent corporate progress. La Jolla Pharmaceutical Company Receives Patent Allowance Covering Broad Range of Modified Pectin
Business Wire - Mon Mar 31, 7:01AM CDT
--Patent Covers Chronic Inflammatory Diseases including Chronic Kidney Disease and NASH
Technical Notes on Top Gainers -- Research on Sequenom, ImmunoCellular Therapeutics, Intellicheck Mobilisa, and La Jolla Pharma
PR Newswire - Thu Mar 20, 7:33AM CDT
On Wednesday, March 19, 2014, the US markets saw a negative sentiment with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including Sequenom Inc. (NASDAQ: SQNM), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), Intellicheck Mobilisa Inc. (AMEX: IDN), and La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Free technical research on SQNM, IMUC, IDN, and LJPC can be downloaded upon signing up at:
5 Stocks Poised for Breakouts
at The Street - Fri Mar 14, 12:25PM CDT
These stocks look ready to break out and trade higher from current levels.
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
Why La Jolla (LJPC) Is Surging Today
at The Street - Tue Mar 11, 2:38PM CDT
La Jolla Pharmaceutical (LJPC) stock is seeing an astronomical rise today on the heels of the news that the clinical trial for its gelectin inhibitor -- used to treat chronic kidney disease -- was a success.
La Jolla's Kidney Drug Is Statistical Noise but Stock Soars
at The Street - Tue Mar 11, 9:02AM CDT
Investors in a biotech stock bubble whistle past legitimate concerns about La Jolla's GCS-100.
La Jolla Pharmaceutical Company Reports Positive, Top-Line Results from Phase 2 Clinical Trial of GCS-100 in Chronic Kidney Disease
Business Wire - Mon Mar 10, 3:15PM CDT
--GCS-100 Well-tolerated
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
La Jolla Pharmaceutical Company to Present at 26th Annual ROTH Growth Stock Conference
Business Wire - Wed Mar 05, 7:01AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that George Tidmarsh, MD, PhD, President and CEO of La Jolla will be presenting a corporate update at the 26th Annual ROTH Conference on March 10, 2014 at 2:30 PM pacific time. An update on the phase 2 clinical study of GCS-100 for the treatment of chronic kidney disease will be included in the presentation. The presentation will be webcast and can be found on the Company's website www.ljpc.com after the presentation. La Jolla Pharmaceutical Company and the George Washington University Enter Into Agreement for Technology Related to LJPC-501
Business Wire - Thu Feb 27, 7:02AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that it has signed an option agreement with the George Washington University ("GW" that will add proprietary technology to the Company's LJPC-501 program. La Jolla Pharmaceutical Company Announces Final Dosing in Phase 2 Clinical Trial of GCS-100 in Chronic Kidney Disease
Business Wire - Fri Feb 21, 7:00AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease ("CKD" and has collected the final data for evaluation of the primary endpoint. The primary efficacy endpoint is the change in estimated glomerular filtration rate ("eGFR" from baseline to the average at Day 50 and 57 in each GCS-100 dose group compared to placebo. The primary endpoint will be reached if the difference in eGFR between either GCS-100 dose group and placebo has a significance of less than 10% (p-value of <0.1). La Jolla Pharmaceutical Company Receives Notice of Allowance for Patent Claims Covering Modified Pectin for Treatment of Chronic Inflammation
Business Wire - Thu Feb 20, 7:00AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that the United States Patent and Trademark Office ("USPTO" has issued a notice of allowance for patent application number 13/888,158 covering methods of treating chronic inflammation using modified pectin. Specifically, the patent, which expires in 2025 without taking into account patent term extension, provides proprietary protection for methods of treating chronic inflammation by administration of modified pectin with a molecular weight greater than 25 kilodaltons. La Jolla Pharmaceutical Company Forms Scientific Advisory Board
Marketwire - Wed Feb 12, 7:02AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a biotechnology company developing therapeutics targeting significant unmet life-threatening diseases, today announced the formation of a Scientific Advisory Board ("SAB" for the development of hepcidin ("LJPC-401" . Inaugural members of the SAB include Tomas Ganz, MD, PhD and Dr. Elizabeta Nemeth, PhD, both of the University of California, Los Angeles ("UCLA" . Dr. Ganz discovered the iron regulator peptide hepcidin and has revolutionized the field of iron biology. Dr. Nemeth has made significant contributions to the field of iron regulation and together with Dr. Ganz, created the first human hepcidin assay. La Jolla Pharmaceutical Company and INSERM, Inserm Transfert Announce License Agreement to Develop Hepcidin Agonists
Marketwire - Mon Feb 10, 3:30PM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
and The French National Institute of Health and Medical Research ("INSERM" , today announced an exclusive worldwide license agreement to develop hepcidin agonists. Hepcidin is the body's master regulator of iron, and patients with insufficient hepcidin levels suffer from chronic iron overload, which can lead to organ and tissue damage. The Company plans to develop hepcidin agonists for the treatment of chronic iron overload in patients who are refractory to or intolerant to chelators. Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
at The Street - Fri Feb 07, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
La Jolla Pharmaceutical Company to Present at the 16th Annual BIO CEO & Investor Conference
Marketwire - Wed Feb 05, 7:15AM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria in New York City on February 10-11, 2014. George F. Tidmarsh, MD, PhD, President and Chief Executive Officer of La Jolla will present on La Jolla's recent progress at 4:30pm Eastern Time on Monday, February 10, in the Conrad Room. The presentation will also be available via webcast on the Company's website at http://www.ljpc.com. 
